A. PERSONAL DETAILS

Full Name: Osman İlhan

Date of Birth: 1955

Foreign Language: English

Position: Lokman Hekim Akay Hospital, Department of Hematology 

E-mail: osmanilhandr@gmail.com  

B. EDUCATIONAL BACKGROUND

The university / faculty of graduation: Ankara University Faculty of Medicine

The year of graduation: 1978

Academic titles: Prof.Dr. 1996

C. INFORMATION ON PROFESSIONAL EXPERIENCE

The institutions / organizations that have worked so far:

1990- Founding Member of Turkey Bone Marrow Transplant Foundation

1993- Ankara University Faculty of Medicine Board Member

1994-Orhan Seyfi Şardaş Founder of Apheresis Unit

1994-Turkey Bone Marrow Foundation Chairman of the Board

1996- Stem Cell Transplantation at MDAnderson Cancer Center, Texas, Therapeutic Apheresis  

          Experience

1997Committee Chair of Turkish Society of Hematology Apheresis  

2000- Founding President of Hemapheresis Association

2001 Board Member of the World Apheresis Association (WAA)

2001- Ministry of Health Apheresis and Photopheresis Commission Presidency

2001 Turkish Hematology Association (1^st Term)

2001 Committee Member of Pharmaceutical Regulatory and Central Ethics Committee of General Directorate for Pharmaceuticals and Pharmacy of Ministry of Health

2002 President of Hemapheresis Association (2^nd Term)

2002-Presidency of Turkish Chronic Myelogenous Leukemia (CML) Working Group

2003- Member of National Cancer Advisory Board of Ministry of Health

2003- Presidency of Turkish Hematology Association (2nd Term)

2003- Ankara Medical Faculty, Department of Hematology  

2003-European Apheresis Association Director of Eastern Europe

 2005- 30^th ISH (World Hematology Association) Congress Presidency

2005- 15^th ESFH (European Apheresis Association) Congress Presidency

2005- EHA (European Hematology Association) CME “Provider Status“

2006- Ministry of Health Bone Marrow Scientific Committee

2006-Turkish Hematology Society Stem Cell Committee Chair

2006- Bone Marrow Transplantation Foundation, President of Turkey

2007- National Organ Tissue Cell Transplantation Coordination Directorate

2007- Ministry of Health Cord Blood Commission

2007- JACIE Turkey Officer

2007- Founding President of Balkan Hematology Association

2007- Head of Stem Cell Research Commission of Ministry of Health

2008- Founding President of Association of Cellular Therapy and Regenerative Medicine

2008- JACIE (Joint Accreditation Committee for ISCT and EBMT) Board Member

2009- 1^st President of National Cellular Therapy Congress

2010- Turkish Golf Federation Board Member

2010- 1^st Chair of National Mesenchymal Stem Cell Symposium

2010 Presidency of Association of Cellular Therapy and Regenerative Medicine (2^nd Term)

2011- 2^nd President of National Cellular Therapy Congress

2011- Founding President of Geriatric Hematology Association

2011- 1^st President of National Geriatric Hematology Symposium

2011-1^st President of International Student Stem Cell Congress

2012- Chair of Cancer Stem Cell Symposium

2012- 15^th WAA (World Apheresis) Congress Honorary President

2012-1^st National Geriatric Hematology Congress

2013- EHA (European Hematology Association) –CME Platinum Certificate

2013- Vice President of WAA

2013- Honorary President of Experimental Hematology Association

2013-2^nd Presidency of Geriatric Hematology Congress

2013-TUBITAK Cellular Treatment CPK membership

2013-2^nd Presidency of International Student Stem Cell Congress

2014- TUBITAK Cellular Treatment Panel Moderatorship

2014-Member of Advisory Board of European Rigosertib

2014-1^st Honorary Chair of National Experimental Hematology Congress

2014- Founding Member of Turkish World Foundation

2014-3^rd National Geriatric Hematology Congress

2015-Founding President of Root Cell Foundation

2015 5^th Presidency of National Cellular Therapy Congress

2015- Science Advisory Board

2015- 4^th National Geriatric Hematology Congress

2016- 5^th National Geriatric Hematology Congress

2017- 6^th Honorary Chair of National Cellular Therapy and Regenerative Medicine Congress

2017- 6^th National Geriatric Hematology Congress

2018- 7^th National Geriatric Hematology Congress

2018- 7^th Honorary Chair of National Cellular Therapy and Regenerative Medicine Congress

2019- 6^th Honorary Chair of Experimental Hematology Congress

2019- Golf Referee, Turkey Golf Federation

D. GENERAL INFORMATION ON CLINICAL RESEARCH

Training on good clinical practice (GCP) and clinical research subjects, the name and date of the institution / organization:

1998- Akademika - Good Clinical Practice Course

2009- Good Clinical Practice Course, General Directorate for Pharmaceuticals and Pharmacy of Ministry of Health

2009- Stem Cell Course

2010- Mesenchymal Stem Cell Course

2010- Good Clinical Practice Training  

2014-Roche School of Clinical Research

2015-Clinical Research Training Program for Ethics Committee Members and Candidates

2019- National and International Project Preparation Training Program

The clinical trials that you participated as a researcher, if any:

2000- Interferon alfaARAC treatment phase III study in New diagnosis CML chronic phase disease

2005- International, Photopheresis Treatment in Graft Versus Host Disease Developed After Allogeneic Stem Cell Transplantation (Phase II)

2006- International, The Place of Mabtheran in Maintenance Treatment in Non-Hodgkin's Lymphoma (NHL 13)

2006- Delivery of Autologous Mononuclear Bone Marrow Cells in Burger's Disease and Heart Failure by Cardiovascular Surgery

2006- A multi-center, randomized, Phase III study, in patients with aggressive B-cell lymphoma, Rituximab used as a maintenance treatment in comparison to observation alone

2007- Impact of Needles of Different Diameters on Viability of Bone Marrow Mononuclear Cells (Master's Thesis)

2008- Collagen Potential of Mesenchymal Stem Cells in Different Hematological Diseases (Dissertation)

2009-A Phase II randomized, open-label, Bosutinib vs. Imatinib Study in newly diagnosed patients with chronic phase Philadelphia chromosome-positive CML

2009-A Multi-center, Open-Labeled, Non-randomized Phase II Study on the Use of Nilotinib as the First Therapy in Adult Patients with Chronic Myeloid Leukemia in the Newly Diagnosed Philadelphia Chromosome-Positive and in Chronic Phase

2010- Randomized phase IIIb study by adding MabThera ® (Rituximab) to chemotherapy with Bendamustine or Chlorambusil in patients with lymphocytic leukemia     

2011- A Randomized, Open, Multi-center, Phase III Study, the Comparison Of Ofatumumab Maintenance Treatment With Observation Only Without Treatment In Response To Induction Chemotherapy In Recurrent CLL

2012- A comparative, randomized, parallel-group, multi-center, phase II study of the efficacy of subcutaneous (SC) rituximab versus intravenous (IV) rituximab in combination with CHOP (R-CHOP) in untreated patients with CD20 positive diffuse large B cell lymphoma (DLBCL)

2012- The head of the project of a comparative analysis of Gene / Micro RNA (miRNA) expression profiles with healthy controls by characterization of bone marrow-derived mesenchymal stem cells (Mkh) in MDS and AML patients

2012-The relation between molecular response to Leukemia stem cell prognosis (Identifying leukemia stem cell-Sokal index relationship) and tyrosine kinase inhibitor treatment in CML

2012-Identifyingmultiple myeloma cancer stem cells by flow cytometry and its effect on prognosis

2013- A phase III, randomized, observer-blind, placebo-controlled, multi-center study to assess reliable and immunogenicity profile when Herpes Zoster HZ /su candidate vaccine of GSK Biologicals was applied to 18 years old and over adults with hematological malignancies with a two-dose regime, administered intramuscularly.

2013- Open-label, single-arm, multi-center, phase II study using Bruton Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Recurrent or Refractory 17p Deletion with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

2013- Multi-center, open-label, single-arm, international Phase IIIB study evaluated for the reliability of Obinutuzumab when used alone or in combination with chemotherapy in untreated or relapsed / refractory Chronic Lymphocytic Leukemia Patients

2014-International Primary Immune Thrombocytopenia (ITP) Multicenter Forward-Looking Disease Registry Study in Adults with Diagnosis

2014- Study towards identifying the frequency of Paroxysmal Nocturnal Hemoglobinuria (PNH) via Regular Scanning of Suspected Patients in Turkey

2014- A randomized, double-blind, parallel-group, placebo-controlled, phase III study comparing the impact of thrombocyte-supporting treatment in placebo patients against placebo by combining azacitidine in patients with moderate-risk group 1, intermediate-risk 2, or high-risk myelodysplastic syndrome (MDS) according to IPSS   

2015- A randomized, multi-center, open-label, phase 3 equivalency study comparing Ibrutinib versus ACP-196 in patients previously treated for high-risk chronic lymphocytic leukemia

2016A phase 3, double-blind randomized study in which the efficiency and reliability of Luspatercept (ACE-536) and placebo in treating anemia in patients with very low, low or moderate risk myelodysplastic syndrome and ring sideroblast in accordance with the revised international prognostic scoring system (IPSS-R) receiving erythrocyte transfusion

20147 Study towards identifying the frequency of Paroxysmal Nocturnal Hemoglobinuria (PNH) via Regular Scanning of Suspected Patients in Turkey

 2018A Randomized Phase 2/3 Study in which a combination of DACOGEN® (Desitabin) Plus Talacotuzumab (JNJ-56022473; AntiCD123) vs. DACOGEN (Decitabine) in AML Patients who are not candidate for Intensive Chemotherapy (56022473AML2002)

2018-Efficiency of Bruton Kinase Inhibitor (Ibrutinib) against Refractory Chronic Graft versus Host Disease : Turkey experience, Retrospective Study

2018-Efficiency of Bruton Kinase Inhibitor (Ibrutinib) in treating Waldenström Macroglobulinemia: Turkey experience, Retrospective Study

2019- A randomized, open-label, phase 3 study in which Efficiency and Reliability Luspatercept (ACE- 536) against Epoetin Alpha

in treating Anemia Patients with

Very Low, Low or Medium Risk Group Myelodysplastic Syndrome (MDS)

according to the Revised International Prognostic Scoring System (IPSS-R)

requiring Erythrocyte Transfusion Untreated with Erythropoiesis Stimulating Agent (ESA)

2019-Efficiency of Ruxolitinib against Refractory Graft versus Host Disease: Turkey experience, Retrospective Study

2019-Efficiency of Bruton Kinase Inhibitor (Ibrutinib) against Refractory Chronic Graft versus Host Disease: Turkey experience, Retrospective Study

2020-Protocol M19-708: Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)